Compare YRD & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | YRD | VRCA |
|---|---|---|
| Founded | 2012 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 88.4M | 88.0M |
| IPO Year | 2015 | 2018 |
| Metric | YRD | VRCA |
|---|---|---|
| Price | $1.00 | $4.62 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $17.00 |
| AVG Volume (30 Days) | 42.1K | ★ 83.3K |
| Earning Date | 06-11-2026 | 05-11-2026 |
| Dividend Yield | ★ 23.28% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $35,577,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $94.44 |
| P/E Ratio | $1.86 | ★ N/A |
| Revenue Growth | N/A | ★ 370.22 |
| 52 Week Low | $0.82 | $3.28 |
| 52 Week High | $6.79 | $9.82 |
| Indicator | YRD | VRCA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 42.61 |
| Support Level | N/A | $4.65 |
| Resistance Level | N/A | $5.94 |
| Average True Range (ATR) | 0.00 | 0.28 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 0.00 | 21.95 |
Yiren Digital Ltd is an AI-powered platform providing a comprehensive suite of financial and lifestyle services in China. Its mission is to elevate customers' financial well-being and enhance their quality of life by delivering digital financial services, tailor-made insurance solutions, and premium lifestyle services. The company supports clients at various growth stages, addressing financing needs arising from consumption and production activities, while aiming to augment the overall well-being and security of individuals, families, and businesses.
Verrica Pharmaceuticals Inc is a therapeutics company developing and commercializing medications for the treatment of dermatologic diseases, including skin cancers. Its commercial product and portfolio of product candidates are clinician administered therapies in areas of high unmet need. This product portfolio consists of one product with an approved indication for molluscum contagiosum, or molluscum, with the potential for several follow-on indications, as well as additional pipeline product candidates. Its commercial product, YCANTH (VP-102), for the treatment of molluscum in adult and pediatric patients two years of age and older. YCANTH (VP-102) is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin.